<DOCUMENT>
<TYPE>EX-10.724
<SEQUENCE>9
<FILENAME>a2104185zex-10_724.htm
<DESCRIPTION>EXHIBIT 10.724
<TEXT>
<HTML>
<HEAD>

</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#03SFO1147_8">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<!-- TOC_END -->
<P ALIGN="RIGHT"><FONT SIZE=2><B>Exhibit&nbsp;10.724  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="li1148_novartis_ag_written_consent_an__nov02406"> </A>
<A NAME="toc_li1148_1"> </A>
<BR></FONT><FONT SIZE=2><B>NOVARTIS AG    <BR>    <BR>    WRITTEN CONSENT AND APPROVAL    <BR>    <BR>    Effective as of May&nbsp;18, 2001    <BR>  </B></FONT></P>

<P><FONT SIZE=2><I>AMENDMENT TO GOVERNANCE AGREEMENT  </I></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, Section&nbsp;2.04 (a)(iv)&nbsp;of that certain Governance Agreement dated as of November&nbsp;20, 1994 between Chiron Corporation ("Chiron" or the
"Company") and Novartis AG, requires the approval of Novartis to change the size of the composition of any committee of the Board of Directors of Chiron; </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS,
the Stock Option Plan Administration Committee (the "Committee") of the Board of Directors of Chiron currently is composed of two Management Directors on Chiron's Board,
S&eacute;an P. Lance and Lewis T. Williams, in accordance with Section&nbsp;2.03(b)(v)&nbsp;of the Governance Agreement; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS,
Dr.&nbsp;Williams has indicated that he will not stand for re-election as a Director at the Annual Stockholders Meeting in May, and will not continue to serve as a
member on the Committee; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS,
Management of Chiron has recommended that it would be in the best interests of the Company to amend Section&nbsp;2.03(b)(v)&nbsp;of the Governance Agreement to reduce the
number of members on the Committee from two to one; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW,
THEREFORE, BE IT RESOLVED, that Section&nbsp;2.03(b)(v)&nbsp;of the Governance Agreement be amended to reduce the number of Management Directors who comprise the members of the
Committee from two (2)&nbsp;to one (1), until such time as the composition of the Committee is otherwise changed in a manner consistent with the Governance Agreement by the Board of Directors, with
such change to be effective as of May&nbsp;18, 2001, subject to Novartis' concurrence; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RESOLVED
FURTHER, that Se&aacute;n P. Lance, who currently serves as the second Management Director and a member of the Committee, continue to serve as the sole Management
Director member of the Committee until his successor is duly elected or qualified; </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN
CONSIDERATION OF THE FOREGOING, Novartis AG hereby approves the reduction in size of the members of the Stock Option Plan Administration Committee of Chiron's Board of Directors and
corresponding amendment of the Governance Agreement with Chiron, effective as of May&nbsp;18, 2001. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="76%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="53%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2>NOVARTIS AG</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="53%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="40%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="53%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="40%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="53%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>By:</FONT></TD>
<TD WIDTH="40%"><FONT SIZE=2>/s/ GEORGE MILLER</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="53%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>Its:</FONT></TD>
<TD WIDTH="40%"><FONT SIZE=2>G. Miller<BR></FONT> <FONT SIZE=2><I>Deputy General Counsel</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="53%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="40%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="53%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="40%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="53%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>By:</FONT></TD>
<TD WIDTH="40%"><FONT SIZE=2>/s/ H. GUT</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="53%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>Its:</FONT></TD>
<TD WIDTH="40%"><FONT SIZE=2>HERBERT GUT<BR></FONT> <FONT SIZE=2><I>Authorized Signatory</I></FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=1,EFW="2104185",CP="CHIRON CORPORATION",DN="8",CHK=738383,FOLIO='blank',FILE='DISK013:[03SFO8.03SFO1148]LI1148A.;7',USER='ATOBAK',CD=';5-MAR-2003;16:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="03SFO1147_8">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_li1148_1">NOVARTIS AG WRITTEN CONSENT AND APPROVAL Effective as of May 18, 2001</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=ATOBAK,SEQ=,EFW="2104185",CP="CHIRON CORPORATION",DN="8" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
